Clinical trials: Locally Advanced Renal Cell Carcinoma
Renal Cell Carcinoma, Stage III Renal Cell Cancer
Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer
Rationale: Diagnostic procedures, such as MRI, may help doctors predict a patient's response to treatment and help plan the best treatment.
- Conditions
- Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT01026337
- Testing
- mutation analysis, pharmacological study, dynamic contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Carcinoma, Renal Cell
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally…
- Trial name
- CONTACT-03 (NCT04338269)
- Testing
- Atezolizumab, Cabozantinib
- Where
- 135 sites in United States, Argentina and 13 more
- Volunteers
- 522 people
- Sponsor
- Hoffmann-La Roche
Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
This phase II trial studies how well ixazomib, gemcitabine, and doxorubicin work in treating patients with kidney cancer that has spread to other places in the body (locally advanced or metastatic).
- Conditions
- Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma, SMARCB1 Negative, Stage III Renal Cell Cancer AJCC v8
- Trial name
- NCT03587662
- Testing
- Doxorubicin, Doxorubicin Hydrochloride, Gemcitabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
This phase II trial investigates the side effects of tocilizumab, ipilimumab, and nivolumab in treating patients with melanoma, non-small cell lung cancer, or urothelial carcinoma that has spread to nearby tissue or lymph nodes…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma, Locally Advanced Bladder Urothelial Carcinoma
- Trial name
- NCT04940299
- Testing
- Ipilimumab, Nivolumab, Tocilizumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Kidney Cancer
Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well atrasentan works in treating patients with locally…
- Trial name
- NCT00039429
- Testing
- atrasentan hydrochloride
- Where
- 177 sites in United States
- Volunteers
- 180 people
- Sponsor
- Eastern Cooperative Oncology Group
Renal Cell Carcinoma, Metastatic Kidney Cancer
Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas
Patients will undergo a screening process as per standard of care to identify disease type and severity. Careful history and physical examination will also take place to rule out major heart, lung, or kidney disease and pregnancy…
- Trial name
- NCT03189186
- Testing
- Pembrolizumab Injection [Keytruda], Cryoablation, Nephrectomy
- Where
- United States
- Sponsor
- University of California, Irvine
Renal Cell Carcinoma (RCC)
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell…
- Trial name
- NCT03260894
- Testing
- Pembrolizumab, Epacadostat, Sunitinib
- Where
- 140 sites in United States, Australia and 18 more
- Volunteers
- 129 people
- Sponsor
- Incyte Corporation
Renal Cell Carcinoma
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™).
- Trial name
- NCT06234605
- Testing
- HC-7366, Belzutifan
- Where
- 21 sites in United States
- Volunteers
- 80 people
- Sponsor
- HiberCell, Inc.
Kidney Cancer
Interferon Alfa in Treating Patients With Advanced Kidney Cancer
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of interferon alfa in treating patients with advanced kidney cancer.
- Trial name
- NCT00003542
- Testing
- pegylated interferon alfa
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
This phase I/II trial tests the safety and effectiveness of inulin gel in combination with ipilimumab and nivolumab in treating patients with kidney cell cancer (renal cell carcinoma [RCC]) that has spread from where it first…
- Conditions
- Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma
- Trial name
- NCT06866262
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Michigan Rogel Cancer Center
Neoplasms
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and…
- Trial name
- NCT02315066
- Testing
- PF-04518600, PF-04518600 plus PF-05082566
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 174 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
This is an exploratory clinical trial to assess the potential of 89Zr-DFO-Atezolizumab Positron Emission Tomography/Computed Tomography (PET/CT) scans in patients with locally advanced or metastatic renal cell carcinoma (RCC).
- Trial name
- NCT04006522
- Testing
- 89Zr-DFO-Atezolizumab, Positron Emission Tomography/Computed Tomography
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- James Brugarolas
Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.
- Conditions
- Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Unresectable Melanoma
- Trial name
- NCT03679767
- Testing
- Retifanlimab
- Where
- 52 sites in United States, Austria and 6 more
- Volunteers
- 121 people
- Sponsor
- Incyte Corporation
Renal Cell Carcinoma (Kidney Cancer), Immunotherapy
Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial
This phase II, multicenter, single-arm, open-label study evaluates first-line ipilimumab N01 plus sintilimab and lenvatinib in patients with locally advanced or metastatic TFE3-rearranged renal cell carcinoma (TFE3-rRCC), a rare…
- Conditions
- Renal Cell Carcinoma (Kidney Cancer), Immunotherapy, Molecular Targeted Therapy
- Trial name
- NCT07715565
- Testing
- Ipilimumab Injection, Sintilimab injection, Lenvatinib
- Where
- China
- Volunteers
- 66 people
- Sponsor
- West China Hospital
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma
Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy
This phase II trial studies how well autologous tumor infiltrating lymphocytes (LN-145) and pembrolizumab work in treating patients with transitional cell cancer that cannot be removed by surgery or has spread to other places in…
- Conditions
- Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma
- Trial name
- NCT03935347
- Testing
- Cyclophosphamide, Fludarabine, Fludarabine Phosphate
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
This phase II trial studies how well adavosertib works in treating patients with SETD2-deficient solid tumors that have spread to other places in the body (advanced/metastatic).
- Conditions
- Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03284385
- Testing
- Adavosertib
- Where
- 29 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
This phase II trial studies how well ceralasertib, am Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, works alone or in combination with olaparib or durvalumab in treating participants with renal cell carcinoma…
- Conditions
- Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03682289
- Testing
- Ceralasertib, Olaparib, Durvalumab
- Where
- 3 sites in United States
- Volunteers
- 83 people
- Sponsor
- Rahul Aggarwal
Renal Cell Carcinoma
CRLX101 Plus Bevacizumab in Advanced RCC
This is a Phase 1b, dose escalation study of the investigational agent, CRLX101, given in combination with Bevacizumab in patients with advanced renal cell carcinoma.
- Trial name
- NCT01625936
- Testing
- CRLX101 (Cerulean), Bevacizumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fluorouracil given as a continuous infusion in treating…
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00003175
- Testing
- fluorouracil
- Where
- 62 sites in Brazil, Canada and 6 more
- Volunteers
- 45 people
- Sponsor
- Medical Research Council
Renal Cancer, Metastases
68Ga-PSMA PET in the Renal Cell Carcinoma
The primary research purpose is to evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced renal cell carcinoma, and to compare with that of enhanced CT.
- Conditions
- Renal Cancer, Metastases, PSMA PET
- Trial name
- NCT04987086
- Testing
- PSMA PET
- Where
- 9 sites in China
- Volunteers
- 300 people
- Sponsor
- Xijing Hospital